KR102669213B1 - 결정 - Google Patents

결정 Download PDF

Info

Publication number
KR102669213B1
KR102669213B1 KR1020127000526A KR20127000526A KR102669213B1 KR 102669213 B1 KR102669213 B1 KR 102669213B1 KR 1020127000526 A KR1020127000526 A KR 1020127000526A KR 20127000526 A KR20127000526 A KR 20127000526A KR 102669213 B1 KR102669213 B1 KR 102669213B1
Authority
KR
South Korea
Prior art keywords
therapeutic agent
crystals
present
crystal
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127000526A
Other languages
English (en)
Korean (ko)
Other versions
KR20120109457A (ko
Inventor
히데유키 이토우
Original Assignee
니뽄 신야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43386634&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102669213(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 니뽄 신야쿠 가부시키가이샤 filed Critical 니뽄 신야쿠 가부시키가이샤
Priority to KR1020247016902A priority Critical patent/KR102829415B1/ko
Priority to KR1020247016901A priority patent/KR102705198B1/ko
Publication of KR20120109457A publication Critical patent/KR20120109457A/ko
Application granted granted Critical
Publication of KR102669213B1 publication Critical patent/KR102669213B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
KR1020127000526A 2009-06-26 2010-06-25 결정 Active KR102669213B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020247016902A KR102829415B1 (ko) 2009-06-26 2010-06-25 결정
KR1020247016901A KR102705198B1 (ko) 2009-06-26 2010-06-25 결정

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JPJP-P-2009-151728 2009-06-26
JPJP-P-2009-151727 2009-06-26
JP2009151727 2009-06-26
JPJP-P-2009-151729 2009-06-26
JP2009151729 2009-06-26
JP2009151728 2009-06-26
PCT/JP2010/060798 WO2010150865A1 (ja) 2009-06-26 2010-06-25 結晶

Related Child Applications (3)

Application Number Title Priority Date Filing Date
KR1020247016901A Division KR102705198B1 (ko) 2009-06-26 2010-06-25 결정
KR1020177005424A Division KR20170024165A (ko) 2009-06-26 2010-06-25 결정
KR1020247016902A Division KR102829415B1 (ko) 2009-06-26 2010-06-25 결정

Publications (2)

Publication Number Publication Date
KR20120109457A KR20120109457A (ko) 2012-10-08
KR102669213B1 true KR102669213B1 (ko) 2024-05-28

Family

ID=43386634

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020127000526A Active KR102669213B1 (ko) 2009-06-26 2010-06-25 결정
KR1020247016901A Active KR102705198B1 (ko) 2009-06-26 2010-06-25 결정
KR1020247016902A Active KR102829415B1 (ko) 2009-06-26 2010-06-25 결정
KR1020257021877A Pending KR20250107951A (ko) 2009-06-26 2010-06-25 결정
KR1020177005424A Ceased KR20170024165A (ko) 2009-06-26 2010-06-25 결정

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020247016901A Active KR102705198B1 (ko) 2009-06-26 2010-06-25 결정
KR1020247016902A Active KR102829415B1 (ko) 2009-06-26 2010-06-25 결정
KR1020257021877A Pending KR20250107951A (ko) 2009-06-26 2010-06-25 결정
KR1020177005424A Ceased KR20170024165A (ko) 2009-06-26 2010-06-25 결정

Country Status (33)

Country Link
US (4) US8791122B2 (https=)
EP (3) EP3275871B1 (https=)
JP (1) JPWO2010150865A1 (https=)
KR (5) KR102669213B1 (https=)
CN (2) CN102459198B (https=)
AR (1) AR077242A1 (https=)
AU (1) AU2010263569B2 (https=)
BR (2) BR122021005510B1 (https=)
CA (1) CA2764475C (https=)
CL (1) CL2011003264A1 (https=)
CO (1) CO6430432A2 (https=)
CY (3) CY1119788T1 (https=)
DK (2) DK3275871T3 (https=)
ES (2) ES2797124T3 (https=)
HR (2) HRP20180171T1 (https=)
HU (3) HUE048467T2 (https=)
IL (3) IL216928A (https=)
LT (3) LT2447254T (https=)
MA (1) MA33637B1 (https=)
MX (2) MX346318B (https=)
MY (1) MY186531A (https=)
NO (2) NO2447254T3 (https=)
NZ (1) NZ597352A (https=)
PH (2) PH12015502824A1 (https=)
PL (2) PL2447254T3 (https=)
PT (2) PT2447254T (https=)
RU (1) RU2556206C3 (https=)
SG (2) SG10201403313WA (https=)
SI (2) SI3275871T1 (https=)
SM (2) SMT201800077T1 (https=)
TW (1) TWI531565B (https=)
WO (1) WO2010150865A1 (https=)
ZA (1) ZA201109099B (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761509A (zh) * 2008-02-28 2015-07-08 日本新药株式会社 纤维化抑制剂
US8575175B2 (en) 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
CN106279047B (zh) * 2015-05-13 2019-05-03 普济生物科技（台州）有限公司 一种前列环素受体激动剂的制备方法
WO2016193994A1 (en) 2015-05-29 2016-12-08 Megafine Pharma (P) Ltd. Amorphous selexipag and process for preparation thereof
WO2017029594A1 (en) * 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Processes for preparation of selexipag and its amorphous form
ES2762943T3 (es) 2015-09-03 2020-05-26 Teva Pharmaceuticals Int Gmbh Formas de Selexipag en estado sólido
WO2017042828A2 (en) * 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Process for the preparation of selexipag and intermediates thereof
WO2017042731A1 (en) 2015-09-10 2017-03-16 Lupin Limited Amorphous form of selexipag and solid dispersion thereof
PT4331607T (pt) * 2015-12-02 2025-05-22 Nippon Shinyaku Co Ltd Composição farmacêutica sólida que contém 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metil-sulfonil)acetamida
WO2017109772A1 (en) * 2015-12-20 2017-06-29 Mapi Pharma Ltd. Amorphous form of selexipag
EP3192502A1 (en) 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag
EP3436439B1 (en) * 2016-04-01 2022-02-16 Honour (R&D) Process for the preparation of diphenylpyrazine derivatives
CN105949135A (zh) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 一种赛乐西帕的合成方法
WO2018008042A1 (en) * 2016-07-05 2018-01-11 Maithri Drugs Private Limited Novel process for the preparation of 2-{4-[(5,6-diphenyl pyrazin-2-yl)(isopropyl)amino]butoxy}-n-(methylsulfonyl)acetamide and novel polymorphs thereof
WO2018015974A1 (en) 2016-07-20 2018-01-25 Mylan Laboratories Limited Polymorphic forms and amorphous solid dispersion of selexipag
WO2018022704A1 (en) * 2016-07-26 2018-02-01 Teva Pharmaceuticals International Gmbh Crystalline form vi of selexipag
WO2018078383A1 (en) 2016-10-27 2018-05-03 Cipla Limited Pharmaceutical composition comprising amorphous selexipag
CN108069914A (zh) * 2016-11-17 2018-05-25 江苏艾立康药业股份有限公司 一种西里帕格晶型的制备方法
MX2019006938A (es) 2016-12-14 2019-09-06 Respira Therapeutics Inc Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
EP3335699A1 (en) 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
BR112020001748A2 (pt) 2017-07-27 2020-07-21 Allergan, Inc. agonistas de receptor de prostaciclina para redução de gordura corporal
MY202100A (en) * 2017-09-28 2024-04-03 Nippon Shinyaku Co Ltd Crystal
CN111565720A (zh) * 2017-11-16 2020-08-21 日本新药株式会社 控释制剂
US10407396B2 (en) 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
JP2021512902A (ja) 2018-02-07 2021-05-20 メッドシャイン ディスカバリー インコーポレイテッド プロスタサイクリン受容体アゴニスト
TW201936175A (zh) * 2018-02-21 2019-09-16 日商日本新藥股份有限公司 粒狀組合物、粒狀組合物之製造方法、及粒狀組合物之溶出性改善方法
CN109125325B (zh) * 2018-09-25 2021-05-25 中国人民解放军总医院 前列环素受体激动剂的医药用途
WO2020157730A1 (en) 2019-02-03 2020-08-06 Patel Jayendrakumar Dasharathlal A controlled release pharmaceutical composition of selexipag or it's active metabolite
EP3705115B1 (en) 2019-03-07 2021-06-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition containing selexipag
JP2022532076A (ja) 2019-05-06 2022-07-13 アクテリオン ファーマシューティカルズ リミテッド サルコイドーシス関連肺高血圧症の治療方法
JP2022533394A (ja) 2019-05-21 2022-07-22 アクテリオン ファーマシューティカルズ リミテッド 肺動脈性肺高血圧症の治療を受けている患者のセレキシパグへの移行方法
EP3982967A1 (en) 2019-06-11 2022-04-20 Actelion Pharmaceuticals Ltd. Methods for treating pulmonary arterial hypertension
WO2021023271A1 (zh) * 2019-08-06 2021-02-11 南京明德新药研发有限公司 作为前列环素受体激动剂的化合物的晶型及其制备方法
CN114555088A (zh) 2019-10-23 2022-05-27 埃科特莱茵药品有限公司 包含赛乐西帕的药物组合物
CA3158292A1 (en) 2019-11-29 2021-06-03 Alessandro MARESTA Methods of treating pulmonary arterial hypertension
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
WO2021152060A1 (en) 2020-01-31 2021-08-05 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
WO2021156227A1 (en) 2020-02-03 2021-08-12 Actelion Pharmaceuticals Ltd Methods of treating and assessing pulmonary arterial hypertension with selexipag
CN112500358B (zh) * 2020-11-18 2022-03-15 江苏豪森药业集团有限公司 赛乐西帕晶型及其制备方法
WO2022106621A1 (en) 2020-11-20 2022-05-27 Actelion Pharmaceuticals Ltd Selexipag for use via intracolonic administration
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative
WO2024133620A1 (en) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd In vitro dissolution test
WO2024142718A1 (ja) * 2022-12-27 2024-07-04 株式会社トクヤマ セレキシパグのｉ型結晶の製造方法
EP4393476A1 (en) * 2022-12-28 2024-07-03 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet formulation comprising selexipag
EP4616904A3 (en) 2022-12-28 2025-10-29 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A formulation comprising selexipag
EP4393475A1 (en) 2022-12-28 2024-07-03 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations comprising selexipag
TW202444370A (zh) 2023-03-23 2024-11-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡衍生物之醫藥組成物
WO2025196095A1 (en) 2024-03-20 2025-09-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition for treating pulmonary hypertension

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092760A1 (en) 2001-03-12 2003-05-15 Toray Industries, Inc. Therapeutic agent for renal failure
WO2000067748A1 (fr) 1999-05-10 2000-11-16 Toray Industries, Inc. Remèdes à l'insuffisance rénale
ES2211738T3 (es) 2000-08-03 2004-07-16 Pfizer Products Inc. Derivados de diazabiciclooctano y sus usos terapeuticos.
JPWO2002085412A1 (ja) * 2001-04-18 2004-08-05 藤沢薬品工業株式会社 組織線維化抑制剤
TWI316055B (https=) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
CN1787824A (zh) 2003-06-25 2006-06-14 有限会社循环器研究所 性交功能改善用外用制剂
US7112393B2 (en) 2003-07-29 2006-09-26 Canon Kabushiki Kaisha Non-magnetic toner
CN104761509A (zh) 2008-02-28 2015-07-08 日本新药株式会社 纤维化抑制剂
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
HRP20151443T1 (hr) 2008-06-23 2016-01-29 Nippon Shinyaku Co., Ltd. Terapijsko sredstvo protiv stenoze kralježniäśnog kanala
CN102065864B (zh) 2008-06-23 2012-11-21 日本新药株式会社 炎性肠病治疗剂
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
US8575175B2 (en) 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
DK2343292T3 (da) 2008-09-10 2014-11-03 Asahi Glass Co Ltd Nyt prostaglandin 12-derivat

Also Published As

Publication number Publication date
HRP20200539T1 (hr) 2020-07-10
PH12015502825A1 (en) 2017-12-11
PT3275871T (pt) 2020-04-21
HUE048467T2 (hu) 2020-07-28
RU2556206C2 (ru) 2015-07-10
RU2012102678A (ru) 2013-08-10
US20140148469A1 (en) 2014-05-29
LT3275871T (lt) 2020-05-11
CL2011003264A1 (es) 2012-07-06
PL2447254T3 (pl) 2018-05-30
JPWO2010150865A1 (ja) 2012-12-10
MY186531A (en) 2021-07-25
US8791122B2 (en) 2014-07-29
LT2447254T (lt) 2018-01-10
US8791122C1 (https=) 2014-07-29
US9284280B2 (en) 2016-03-15
KR20120109457A (ko) 2012-10-08
BR122021005510B1 (pt) 2022-01-11
KR20250107951A (ko) 2025-07-14
IL243293A0 (en) 2016-02-29
KR102829415B1 (ko) 2025-07-03
CY2018011I1 (el) 2018-09-05
US20150266830A1 (en) 2015-09-24
CA2764475C (en) 2017-04-25
PL3275871T3 (pl) 2020-07-27
US20120101276A1 (en) 2012-04-26
IL216928A0 (en) 2012-02-29
ZA201109099B (en) 2012-08-29
MX2011013471A (es) 2012-01-30
AU2010263569B2 (en) 2016-08-18
IL243287A0 (en) 2016-02-29
LTC2447254I2 (lt) 2022-04-25
CN104326991A (zh) 2015-02-04
NZ597352A (en) 2013-01-25
US9340516B2 (en) 2016-05-17
CY2018011I2 (el) 2018-09-05
PH12015502825B1 (en) 2017-12-11
HK1244788A1 (en) 2018-08-17
CN102459198A (zh) 2012-05-16
CA2764475A1 (en) 2010-12-29
HUE036721T2 (hu) 2018-07-30
CY1119788T1 (el) 2018-06-27
KR20240090716A (ko) 2024-06-21
US9440931B2 (en) 2016-09-13
WO2010150865A1 (ja) 2010-12-29
SG10201403313WA (en) 2014-10-30
SMT202000177T1 (it) 2020-05-08
EP2447254A4 (en) 2012-12-19
SG176915A1 (en) 2012-01-30
LTPA2018008I1 (lt) 2018-05-10
CN102459198B (zh) 2014-09-24
TWI531565B (zh) 2016-05-01
EP3275871A1 (en) 2018-01-31
ES2797124T3 (es) 2020-12-01
TW201111352A (en) 2011-04-01
KR20240090717A (ko) 2024-06-21
ES2660007T3 (es) 2018-03-20
HRP20180171T1 (hr) 2018-03-09
HUS1800015I1 (hu) 2018-05-28
KR102705198B1 (ko) 2024-09-11
NO2447254T3 (https=) 2018-05-05
IL243287B (en) 2021-04-29
SI3275871T1 (sl) 2020-06-30
AR077242A1 (es) 2011-08-10
SMT201800077T1 (it) 2018-03-08
IL216928A (en) 2016-10-31
CO6430432A2 (es) 2012-04-30
MA33637B1 (fr) 2012-10-01
PT2447254T (pt) 2018-01-04
SI2447254T1 (en) 2018-03-30
PH12015502824A1 (en) 2017-05-29
CY1122893T1 (el) 2021-05-05
KR20170024165A (ko) 2017-03-06
EP3689855A1 (en) 2020-08-05
DK2447254T3 (en) 2018-01-15
EP2447254A1 (en) 2012-05-02
US20140155414A1 (en) 2014-06-05
AU2010263569A1 (en) 2012-02-02
EP3275871B1 (en) 2020-01-15
BRPI1015936B1 (pt) 2021-07-13
EP2447254B1 (en) 2017-12-06
NO2018015I1 (no) 2018-04-23
BRPI1015936A2 (pt) 2016-08-16
RU2556206C3 (ru) 2021-06-15
MX346318B (es) 2017-03-15
DK3275871T3 (da) 2020-04-06

Similar Documents

Publication Publication Date Title
KR102669213B1 (ko) 결정
JP2022173401A (ja) 結晶
HK1165421B (en) Crystals
HK1244788B (en) Crystals
HK1165421A (en) Crystals

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150622

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160705

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170102

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160705

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170224

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170102

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160913

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170414

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170224

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170102

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160913

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160705

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20170516

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20170414

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20170102

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20181116

Appeal identifier: 2017101002375

Request date: 20170516

J301 Trial decision

Free format text: TRIAL NUMBER: 2017101002375; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20170516

Effective date: 20181116

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20181116

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20170516

Decision date: 20181116

Appeal identifier: 2017101002375

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2019201001377; APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20181116

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20191004

Appeal identifier: 2019201001377

Request date: 20190118

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2019201001377; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20190118

Effective date: 20191004

PJ1302 Judgment (patent court)

Patent event date: 20191005

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20190118

Decision date: 20191004

Appeal identifier: 2019201001377

Appeal kind category: Appeal against decision to decline refusal

J2X2 Appeal (before the supreme court)

Free format text: TRIAL NUMBER: 2019301011800; APPEAL BEFORE THE SUPREME COURT FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2002 Appeal before the supreme court

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event date: 20181116

Patent event code: PJ20021S01I

Request date: 20191227

Appeal identifier: 2019301011800

Appeal kind category: Appeal against decision to decline refusal

PJ2201 Remand (intellectual property tribunal)

Patent event code: PJ22012S01I

Comment text: Written Judgment (Patent Court)

Patent event date: 20230918

Request date: 20230918

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2023131000019

J301 Trial decision

Free format text: TRIAL NUMBER: 2023131000019; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20230918

Effective date: 20231218

PJ1301 Trial decision

Patent event code: PJ13011S09D

Patent event date: 20231218

Comment text: Trial Decision on Final Judgment on Revocation

Appeal kind category: Appeal against decision to decline refusal

Request date: 20230918

Decision date: 20231218

Appeal identifier: 2023131000019

PS0901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20240221

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20231228

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240521

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240522

End annual number: 3

Start annual number: 1

PG1601 Publication of registration